Study guide

14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances

Key Takeaways Explain This Topic AI

Under low-dose linear (mutagenic) cancer assessment, extra lifetime risk ≈ CSF × LADD, with CSF in (mg/kg-day)^−1 and LADD in mg/kg-day. Using ADD instead of LADD inflates risk by mixing averaging times.

Inhalation extra risk ≈ IUR × lifetime-equivalent concentration when units match (for example IUR per µg/m³ times µg/m³). Do not multiply an oral CSF by an air µg/m³ without dosimetry.

EPA Superfund decision context for known or suspected carcinogens is generally an excess upper-bound lifetime individual risk range of 10^−6 to 10^−4; 10^−6 is often the screening point of departure for remediation goals.

Occupational cancer-risk tolerances differ from Superfund community values; OSHA significant-risk discussion historically includes lifetime risks on the order of 10^−3. Different statutes and populations, not a single number.

ABT does not publish a universal acceptable-cancer-risk constant. Named programs (Superfund, OSHA, Proposition 65, some drinking-water goals) each state their own decision context.

Last updated: September 2026

Extra lifetime risk is a characterization, not a tumor count

Handbook III.D.1 still applies when the apical effect is cancer . Hazard identification may have classified the agent; dose–response may have produced a cancer slope factor (CSF) or inhalation unit risk (IUR) (Chapter 12). Characterization asks what extra lifetime cancer risk that slope implies at this exposure, and which named decision context —not a folkloric “safe number”—you are using to interpret it. Independent ExamFinch teaching in this section covers Risk ≈ CSF × LADD , IUR × concentration , the EPA Superfund 10^−6 to 10^−4 range, occupational tolerances that are not Superfund clones, and why ABT has not published a universal acceptable-risk constant. It is not an ABT, EPA, or OSHA product and does not claim official approval, review, or partnership with those bodies.

EPA slope factors used in Superfund-style work are typically upper-bound (often a 95% upper confidence limit on the slope). The product is therefore an upper-bound extra lifetime individual risk , not a prediction of next year’s case count in a census tract and not a proof that the central-estimate risk equals that number.

CSF × LADD (oral, low-dose linear)

For a linear no-threshold oral assessment (the EPA 2005 mutagenic default):

Extra lifetime risk ≈ CSF × LADD

CSF has units of (mg/kg-day)^−1 . LADD is the lifetime average daily dose in mg/kg-day, with averaging time 70 years × 365 days (Chapter 11). ADD (averaging time = exposure duration) is the noncancer input. Putting ADD into a lifetime CSF overstates risk whenever exposure lasts less than a lifetime, because the same ingested milligrams are not spread over 70 years.

Worked residential water example. Concentration C = 0.002 mg/L , adult intake 2 L/day , body weight 70 kg , exposure duration 30 years , every day, cancer averaging time 70 years .

LADD = (C × IR × ED) / (BW × 70) when EF = 365 (the 365 cancels).

C × IR = 0.002 × 2 = 0.004 mg/day .

LADD = 0.004 / 70 × (30 / 70) = 0.00005714 × 0.42857 = 2.45 × 10^−5 mg/kg-day .

Check with totals: numerator 0.004 × 365 × 30 = 43.8 mg ; denominator 70 × 25,550 = 1,788,500 kg·day ; 43.8 / 1,788,500 = 2.45 × 10^−5 mg/kg-day .

If CSF = 0.41 (mg/kg-day)^−1 , extra risk = 0.41 × 2.45 × 10^−5 = 1.0 × 10^−5 (one extra case in 100,000 upper-bound individual lifetime risk, as a teaching product).

If a reviewer instead used ADD = 0.004 / 70 = 5.71 × 10^−5 mg/kg-day (30-year average, no 70-year stretch), risk would be 0.41 × 5.71 × 10^−5 = 2.3 × 10^−5 —about 70/30 = 2.33 times higher, which is exactly ADD/LADD. That is an averaging-time error, not a more conservative statute.

Unit risk × concentration (inhalation)

Inhalation unit risk (IUR) is extra lifetime risk per unit air concentration , commonly per µg/m³ . When the exposure metric is already a lifetime-equivalent concentration :

Extra risk ≈ IUR × C

Worked IUR. IUR = 2.5 × 10^−6 per µg/m³ ; lifetime-equivalent concentration C = 8 µg/m³ . Risk = 2.5 × 10^−6 × 8 = 2.0 × 10^−5 .

Do not multiply an oral CSF by an air concentration in µg/m³. The units are incommensurate until you convert air to a mg/kg-day intake with a defensible inhalation rate and bioavailability—and Superfund RAGS Part F prefers to keep inhalation as a concentration compared with an IUR or RfC. An 8-hour occupational TWA is not a lifetime-equivalent concentration until you apply the hours/24 and days/7 (and working-year versus 70-year) adjustments the scenario actually needs.

Oral drinking-water unit risk is the cousin: extra risk per µg/L (or per mg/L) in water under specified consumption and body-weight assumptions. It is still unit risk × concentration , with the unit risk already folding in those assumptions. Mixing a water unit risk with an air µg/m³ is the same unit error.

Superfund’s 10^−6 to 10^−4 decision context

Under the National Contingency Plan, EPA Superfund generally discusses acceptable exposure levels for known or suspected carcinogens as concentrations corresponding to an excess upper-bound lifetime individual risk between 10^−4 and 10^−6 (1 in 10,000 to 1 in 1,000,000). 10^−6 is often the point of departure for setting preliminary remediation goals when other applicable or relevant and appropriate requirements do not control: below about 10^−6, cancer risk commonly drops out of the action discussion; between 10^−6 and 10^−4 , risk managers weigh feasibility, other health endpoints, and community factors; above 10^−4 , action is more often expected. That range is a Superfund decision context . It is not a biological threshold, not a drinking-water MCL by itself, and not an occupational PEL.

The water example at 1.0 × 10^−5 sits inside that range: above the 10^−6 screening departure, below the 10^−4 upper end. The IUR example at 2.0 × 10^−5 sits in the same band. Neither number is “acceptable” or “unacceptable” until the program is named.

The bar chart in this section plots those magnitudes as extra cases per million people for teaching: 1 (10^−6), 10 (10^−5), 100 (10^−4), and 1,000 (10^−3, the occupational-order figure in the next heading). It is a scale diagram, not a regulatory table of approved limits.

Occupational cancer-risk tolerances differ

Workplace statutes protect adult workers , usually over a working lifetime , not 24-hour residential children. In Industrial Union Department v. American Petroleum Institute (the 1980 benzene decision), the U.S. Supreme Court discussed significant risk in occupational health in terms that OSHA has long treated as including lifetime risks on the order of 10^−3 (1 in 1,000). OSHA then sets feasible standards; a PEL is not a Superfund 10^−6 cleanup goal rewritten for factories. ACGIH TLVs are health-based recommendations with a different method and no claim to a 10^−6 individual-risk calculation. Comparing a factory TWA with a Superfund PRG without restating population, duration, and statute is a characterization error.

Other named programs use other lines. California Proposition 65 no-significant-risk levels are often built around 10^−5 extra lifetime risk. Some drinking-water cancer discussions use 10^−6 or 10^−5 as a goal while MCLs remain technology- and feasibility-constrained. WHO/EFSA food work may stay in MOE language (section 14.1) rather than CSF × LADD. Learn to name the program .

Named program / context Typical extra-lifetime-risk discussion Whose exposure

EPA Superfund (NCP) Generally 10^−6 to 10^−4 upper-bound individual lifetime extra risk; 10^−6 often the screening point of departure Residents and other site receptors, including children

OSHA significant-risk discussion (benzene decision lineage) Order of 10^−3 ; PELs then constrained by feasibility Adult workers, working lifetime

California Proposition 65 NSRL Often built around 10^−5 General public under that statute

EFSA food genotoxic-carcinogen MOE MOE from BMDL10, with 10,000 as a low-concern discussion point (section 14.1)—not a CSF × LADD line Dietary consumers

ABT / DABT handbook No published universal acceptable-cancer-risk constant Examination tests method, not a secret cutoff

What ABT does not publish

The DABT examination tests whether you can compute extra risk and place it in a stated framework . ABT has not published a single acceptable-cancer-risk number that applies to Superfund, OSHA, food contaminants, and drugs. Inventing “the DABT limit is 10^−6” is the same class of error as inventing a numeric passing score. Report the calculated risk , the averaging time , the upper-bound versus central-estimate status, and the decision context you actually invoked .

Scenario

A Superfund risk assessor reports CSF × LADD = 1.0 × 10^−5 for residents and IUR × C = 2.0 × 10^−5 for indoor air after vapor-intrusion adjustment. Both sit in the 10^−6–10^−4 Superfund band; neither is automatically “safe” or “close the site.” A plant industrial hygienist notes that the same chemical’s OSHA discussion historically tolerated ~10^−3 theoretical lifetime risk at the PEL and concludes Superfund must therefore use 10^−3 for the neighboring houses. That conclusion imports the wrong statute and the wrong receptor . A third reviewer multiplies the oral CSF of 0.41 (mg/kg-day)^−1 by 8 µg/m³ and reports risk = 3.28, which is unit-free nonsense. Air belongs with an IUR , or with a converted intake that is then multiplied by a CSF after documenting the conversion.

Traps

Using ADD in CSF × dose, or LADD against an RfD.

Treating 10^−6 as a biological zero, or 10^−4 as a license to ignore risk.

Declaring a universal “acceptable risk” as if ABT or a single EPA office issued one number for all statutes.

Multiplying oral CSF by air µg/m³, or IUR by mg/kg-day.

Equating OSHA significant-risk language (~10^−3) with Superfund residential PRGs.

Reporting extra risk as next year’s observed cases without an exposed population and a central estimate.

Illustrative extra lifetime cancer-risk magnitudes (cases per million)